GB201522433D0 - Cancer treatment - Google Patents
Cancer treatmentInfo
- Publication number
- GB201522433D0 GB201522433D0 GBGB1522433.0A GB201522433A GB201522433D0 GB 201522433 D0 GB201522433 D0 GB 201522433D0 GB 201522433 A GB201522433 A GB 201522433A GB 201522433 D0 GB201522433 D0 GB 201522433D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- High Energy & Nuclear Physics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522433.0A GB201522433D0 (en) | 2015-12-18 | 2015-12-18 | Cancer treatment |
PCT/GB2016/053991 WO2017103625A1 (en) | 2015-12-18 | 2016-12-19 | Cancer treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522433.0A GB201522433D0 (en) | 2015-12-18 | 2015-12-18 | Cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201522433D0 true GB201522433D0 (en) | 2016-02-03 |
Family
ID=55311264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1522433.0A Ceased GB201522433D0 (en) | 2015-12-18 | 2015-12-18 | Cancer treatment |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201522433D0 (en) |
WO (1) | WO2017103625A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107693509A (en) * | 2017-11-22 | 2018-02-16 | 中国医药集团总公司四川抗菌素工业研究所 | SB FI 26 are preparing the application in treating breast cancer medicines |
WO2022049529A2 (en) * | 2020-09-04 | 2022-03-10 | Aurigene Discovery Technologies Limited | Method of treating cancer using fabp5 inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056631A1 (en) * | 2008-11-12 | 2010-05-20 | Schering Corporation | Inhibitors of fatty acid binding protein (fabp) |
-
2015
- 2015-12-18 GB GBGB1522433.0A patent/GB201522433D0/en not_active Ceased
-
2016
- 2016-12-19 WO PCT/GB2016/053991 patent/WO2017103625A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2017103625A1 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3197456T3 (en) | Cancer treatments | |
IL259996A (en) | Combinations for the treatment of cancer | |
IL263802A (en) | Cancer treatment combinations | |
HK1231561A1 (en) | Cancer treatment | |
GB201502137D0 (en) | Treatment | |
PT3576740T (en) | Cancer treatment | |
GB201706451D0 (en) | Cancer treatment | |
GB201522243D0 (en) | Treatment | |
IL268463A (en) | Cancer treatment | |
GB201409363D0 (en) | Skin cancer treatment | |
HK1251794A1 (en) | Cancer treatment | |
GB201508841D0 (en) | Treatment | |
ZA201707024B (en) | Cancer treatment composition | |
GB201707864D0 (en) | Platinum-reistant cancer treatment | |
IL274626A (en) | Cancer treatment | |
GB201519734D0 (en) | Cancer therapy | |
GB201522433D0 (en) | Cancer treatment | |
HK1254687A1 (en) | Combination therapy for cancer | |
GB201503008D0 (en) | Treatment | |
HRP20210383T8 (en) | Combination therapy for cancer | |
GB201713852D0 (en) | Cancer treatment | |
GB201514777D0 (en) | Cancer Treatments | |
GB201511609D0 (en) | Cancer therapy | |
GB201511121D0 (en) | Cancer therapy | |
GB201511120D0 (en) | Cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |